Resilience Therapeutics, Inc. (Resilience) and PGI Drug Discovery LLC (PsychoGenics), recently announced that they have entered into a partnership to discover and optimize novel treatments for Post-Traumatic Stress Disorder (PTSD) and related conditions.
World Fusion Co., LTD and Lumenogix Inc. recently announced a strategic partnership to provide a complete solution for the pharmaceutical industry that integrates the World Fusion Life Sciences Knowledge Bank (LSKB) for accelerating drug discovery with the Lumenogix Bioinformatics-in-a-Box™ for analyzing Next Generation Sequencing (NGS) data.
20/20 HealthCare Partners LLC (20/20 HCP), a global investment group focused on early stage medical technology and life science innovation, recently announcd an agreement with Roche, in which they will source and identify novel treatments and/or technologies in the biotech arena. These areas include oncology/immuno-oncology, neurology, infectious diseases, inflammation and ophthalmology.
Strand Genomics Inc. And BioHealth Innovation, Inc. Partner To Expand Strand Centers For Genomics & Personalized Medicine In The U.S.
Strand Genomics Inc. (Strand) and BioHealth Innovation, Inc. (BHI) recently announced a strategic partnership designed to expand the Strand Centers for Genomics & Personalized Medicine into the U.S. This effort is intended to help revolutionize access to genomic interpretation services in cardiovascular disease, oncology, rare diseases, and many other indications. Strand Genomics is a wholly owned subsidiary of Strand Life Sciences, a Bangalore, India-based bioinformatics, clinical genomics, and diagnostics company.
Bayer HealthCare to Collaborate with Sysmex Inostics GmbH to Develop Blood-based Companion Diagnostic Tests in Oncology
Bayer HealthCare has entered into a master collaboration agreement with the diagnostic company Sysmex Inostics GmbH for the development of companion diagnostics for targeted cancer therapies. The innovative blood-based companion diagnostic solutions offered by Sysmex Inostics will complement anti-cancer agents developed by Bayer.